MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 21.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,967 shares of the company's stock after purchasing an additional 14,125 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.09% of CRISPR Therapeutics worth $3,143,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in CRSP. Western Pacific Wealth Management LP grew its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after buying an additional 500 shares during the period. Spire Wealth Management lifted its stake in CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after purchasing an additional 1,482 shares in the last quarter. MCF Advisors LLC bought a new stake in CRISPR Therapeutics in the 4th quarter valued at about $80,000. First Horizon Advisors Inc. raised its stake in shares of CRISPR Therapeutics by 33.4% in the 4th quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company's stock valued at $80,000 after buying an additional 511 shares in the last quarter. Finally, Elkhorn Partners Limited Partnership raised its stake in shares of CRISPR Therapeutics by 22.6% during the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,800 shares of the company's stock worth $150,000 after buying an additional 700 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research report on Thursday, February 13th. The Goldman Sachs Group cut their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Morgan Stanley raised their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a report on Friday, February 14th. Finally, TD Cowen upgraded CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective on the stock in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $71.75.

Insider Transactions at CRISPR Therapeutics

In related news, Director John Greene acquired 7,000 shares of the firm's stock in a transaction on Wednesday, February 26th. The stock was bought at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the purchase, the director now directly owns 7,000 shares of the company's stock, valued at approximately $313,950. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the sale, the chief executive officer now directly owns 180,890 shares of the company's stock, valued at approximately $7,673,353.80. This represents a 5.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,021 shares of company stock worth $594,771. Insiders own 4.30% of the company's stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP traded down $0.67 during mid-day trading on Friday, hitting $36.86. The company had a trading volume of 1,256,881 shares, compared to its average volume of 1,690,987. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $67.88. The stock has a market cap of $3.18 billion, a price-to-earnings ratio of -8.43 and a beta of 1.88. The firm's 50 day simple moving average is $37.05 and its two-hundred day simple moving average is $41.87.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. CRISPR Therapeutics's revenue was up 71.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.43) earnings per share. Equities analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.